Home page  |  Help  |  Clear
English  |  French
 Search  |  Categories  |  Titles A-Z  |  Countries  |  Compare countries  |  Index  
Full TOC
Expand Document
Expand Chapter
Preferences

close this bookClinical Guidelines for Diagnosis and Treatment of Common Conditions in Kenya (WHO; 2002; 344 pages)
View the documentFOREWORD
View the documentPREFACE
View the documentACKNOWLEDGEMENTS
View the documentABBREVIATIONS
Open this folder and view contents1. ACUTE INJURIES AND TRAUMA & SELECTED EMERGENCIES
Open this folder and view contents2. AIDS & SEXUALLY TRANSMITTED INFECTIONS
Open this folder and view contents3. CARDIOVASCULAR DISEASES
Open this folder and view contents4. CENTRAL NERVOUS SYSTEM
Open this folder and view contents5. DENTAL AND ORAL CONDITIONS
Open this folder and view contents6. EAR, NOSE AND THROAT CONDITIONS
Open this folder and view contents7. ENDOCRINE SYSTEM CONDITIONS
Open this folder and view contents8. EYE CONDITIONS
Open this folder and view contents9. FAMILY PLANNING
Open this folder and view contents10. GASTROINTESTINAL CONDITIONS
View the document11. IMMUNIZATION
Open this folder and view contents12. INFECTIONS (SELECTED) & RELATED CONDITIONS
close this folder13. MENTAL DISORDERS
View the document13.1. ACUTE CONFUSION (Acute Psychosis)
View the document13.2. ALCOHOL WITHDRAWAL (Delirium tremens)
View the document13.3. SUBSTANCE ABUSE RELATED DISORDERS
View the document13.4. ANXIETY
View the document13.5. CHILDHOOD PSYCHIATRIC DISORDER
View the document13.6. CONVERSION SYNDROMES
View the document13.7. DEPRESSION
View the document13.8. BIPOLAR MOOD DISORDER (MANIC EPISODE)
View the document13.9. SCHIZOPHRENIA
View the document13.10. SLEEP DISORDERS
View the document13.11. SUICIDE ATTEMPTS
View the document13.12. VALUE OF ELECTRO-CONVULSIVE THERAPY (ECT)
Open this folder and view contents14. MUSCULOSKELETAL CONDITIONS
Open this folder and view contents15. NEONATAL CARE & CONDITIONS
Open this folder and view contents16. NEOPLASMS
Open this folder and view contents17. NUTRITIONAL AND HAEMATOLOGIC CONDITIONS
Open this folder and view contents18. OBSTETRIC AND GYNAECOLOGICAL CONDITIONS
Open this folder and view contents19. ORTHOPAEDICS
View the document20. POISONING
Open this folder and view contents21. RESPIRATORY DISEASES
Open this folder and view contents22. SIGNS & SYMPTOMS
Open this folder and view contents23. SKIN DISEASES
Open this folder and view contents24. SURGERY
Open this folder and view contents25. Genito-urinary Diseases: Urinary Tract & Renal Conditions
Open this folder and view contentsAnnexes
 

13.9. SCHIZOPHRENIA

A form of mental illness which is characterised by loss of contact with reality, hallucination, delusions, abnormal thinking, flattened effect, and disturbed work and social function, occurring in a setting of clear consciousness memory and orientation.

Clinical Features

Withdrawal Generalised loss of interest in the environment. Thought disorder. Normal association of ideas is lost. Incongruency of affect is characteristic. Delusions. Hallucinations in any sensory modality. Disturbances in behaviour and motor function e.g. grimacing, odd postures, etc. History from patient and relatives is most important. Continuous signs of illness should be present for 6 months at some point in patient's life, with some signs at the time of diagnosis.

Management - General

• Psychological and Social.


Use psychiatric community nurses and social workers in involving family to understand the illness and helping the family in rehabilitation of the patient into community activities. Importance of drug compliance should be explained to relatives and patients.

Management - Pharmacologic

• Severely disturbed patient - admit;

- give chlorpromazine 100-200 mg IM and then start on oral chlorpromazine 100- 200 mg TDS OR haloperidol 5-10 mg TDS

• Mildly disturbed patient:

- manage as outpatient;

- give chlorpromazine 100 mg TDS OR haloperidol 5 mg TDS. If patient was diagnosed as a schizophrenic and missed his drugs, restart the drug as before

• Maintenance therapy, chlorpromazine 100-200 mg TDS OR haloperidol 5-10 mg TDS

• Onset of extra pyramidal side effects: reduce dose and start on benzhexol 2.5-5 mg TDS

• For patients who are not dependable about taking oral drug, depot preparations are available;

- fluphenazine decanoate 25 mg IM monthly

- haloperidol decanoate 50 mg IM monthly

- clopenthixol decanoate 200 mg IM monthly

- flupenthixol decanoate 40 mg IM monthly.


Caution: Aim to use lowest dose that is therapeutic in cases of long term use to minimize risk of side effects.

Refer If

• Poor compliance

• Inadequate dosage/therapeutic treatment up to 6 weeks

• Misdiagnosis.


Admit

• If patient is severely disturbed, violent or catatonic.


Patient Education

• Compliance to therapy is important to prevent relapses

• Relatives should bring the patient to the hospital at early signs of relapse

• Drugs may have to be taken for a long time depending on response.

to previous sectionto next section

Please provide your feedback
Abbreviations
English  |  French